Sigilon Stock Analysis

SGTX -  USA Stock  

USD 5.28  0.29  5.21%

The big decline in price over the last few months for Sigilon Therapeutics created some momentum for investors as it was traded today as low as 5.25 and as high as 5.86 per share. The company management teams failed to add value to investors and positioning the company supply of money to exploit market volatility in June. However, diversifying your holdings with Sigilon Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Sigilon Therapeutics partners.
Additionally, take a look at World Market Map.

Search Stock Analysis 

The Sigilon Therapeutics stock analysis report makes it easy to digest most publicly released information about Sigilon Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Sigilon Stock analysis module also helps to analyze the Sigilon Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Sigilon Stock Analysis Notes

The company had not issued any dividends in recent years. Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about Sigilon Therapeutics contact the company at 617-336-7540 or learn more at

Sigilon Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Sigilon Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Sigilon Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Sigilon Therapeutics generates negative expected return over the last 90 days
Sigilon Therapeutics has high historical volatility and very poor performance
Sigilon Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 12.72 M. Net Loss for the year was (52.48 M) with loss before overhead, payroll, taxes, and interest of (33.95 M).
Sigilon Therapeutics currently holds about 76.07 M in cash with (57.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from Sigilon Therapeutics Inc gains 2.21 percent for July 21 -

Sigilon Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Sigilon Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sigilon Therapeutics backward and forwards among themselves. Sigilon Therapeutics' institutional investor refers to the entity that pools money to purchase Sigilon Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Soundmark Wealth Management LlcCommon Shares55.6 K595 K
Flagship Pioneering IncCommon Shares10.4 M231.8 M
Canada Pension Plan Investment BoardCommon Shares1.5 M33.2 M
Blackrock IncCommon Shares1.3 M28.7 M
Avidity Partners Management LpCommon Shares851 K19 M
Fmr LlcCommon Shares811.2 K18.1 M
Harbourvest Partners LlcCommon Shares740.7 K16.6 M
Note, although Sigilon Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Management Efficiency

Sigilon Therapeutics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of July, Sigilon Therapeutics has the coefficient of variation of (411.89), and Risk Adjusted Performance of (0.17). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sigilon Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Sigilon Therapeutics, which can be compared to its competition. Please validate Sigilon Therapeutics downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Sigilon Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 5.28 per share. Given that Sigilon Therapeutics has jensen alpha of (1.27), we advise you to double-check Sigilon Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Sigilon Therapeutics Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Exponential Moving Average is calculated by weighting recent values of Sigilon Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Sigilon Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sigilon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sigilon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sigilon Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Sigilon Therapeutics Predictive Daily Indicators

Sigilon Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sigilon Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Sigilon Therapeutics Forecast Models

Sigilon Therapeutics time-series forecasting models is one of many Sigilon Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sigilon Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Sigilon Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sigilon Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sigilon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Sigilon Therapeutics. By using and applying Sigilon Stock analysis, traders can create a robust methodology for identifying Sigilon entry and exit points for their positions.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Sigilon Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Anywhere Now


Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Sigilon Therapeutics information on this page should be used as a complementary analysis to other Sigilon Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Sigilon Stock analysis

When running Sigilon Therapeutics price analysis, check to measure Sigilon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sigilon Therapeutics is operating at the current time. Most of Sigilon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sigilon Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Sigilon Therapeutics' price. Additionally, you may evaluate how the addition of Sigilon Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
The market value of Sigilon Therapeutics is measured differently than its book value, which is the value of Sigilon that is recorded on the company's balance sheet. Investors also form their own opinion of Sigilon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sigilon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sigilon Therapeutics' market value can be influenced by many factors that don't directly affect Sigilon Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sigilon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Sigilon Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sigilon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.